Aktie 868125 H.U. GROUP HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen H.U. Group Holdings, Inc.

Aktien

868125

JP3822000000

4544

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 26.04.2024 		% 5 Tage % 1. Jan.
2’416 JPY +0.86% Intraday Chart für H.U. Group Holdings, Inc. +3.85% -9.29%
26.04. H.U. Group Holdings, Inc. kündigt Rücktritt von Atsuko Murakami als Executive Officer an CI
13.03. Fujirebio und Beckman Coulter erweitern Partnerschaft zur Entwicklung patientenfreundlicher, blutbasierter Diagnostika für neurodegenerative Erkrankungen CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer
H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook
H.U. Group to Issue Stock Options to Directors, Employees
H.U. Group to Grant Share Options to Staff
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index
Recent DOJ Settlement With NextGen Highlights Continued Enforcement Focus On Electronic Health Records Technology Vendors
H.U. Group Holdings' Fiscal Full-Year Profit Falls 47%
H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
H.U. Group Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
H.U. Group Holdings Inc. - Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for Research Use Only
Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood tests
H.U. Group Holdings, Inc. Announces Launch of the Fully Automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023
H.U. Group Holdings, Inc. Provides Year End Dividend Forecast for the Fiscal Year Ending March 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 868125 Aktie
  4. Nachrichten H.U. Group Holdings, Inc.
  5. Andere Sprachen